SINUS-52

DUPIXENT significantly decreased sinus opacification vs placebo, as measured by LMK-CT score at Week 24 (key secondary endpoint) with sustained improvement through Week 52 (other secondary endpoint) in SINUS-52.^4,a

DUPIXENT (300 mg Q2W + INCS) demonstrated a 27% improvement at Week 24 from a baseline score of 18.12 (n=295, pooled arms) vs 1% improvement with placebo from a baseline score of 17.65 (n=153) (LSM difference vs placebo: -5.13 [95% CI: -5.80, -4.46]) and 38% improvement at Week 52 from a baseline score of 18.42 (n=150) vs 2% worsening with placebo from a baseline score of 17.65 (n=153) (LSM difference vs placebo: -6.94 [95% CI: -7.87, -6.01]). DUPIXENT demonstrated statistically significant reductions in opacification across all sinuses at Week 24.⁴

^a Analysis of change at Week 52 was not multiplicity controlled; result is descriptive.⁴

CI, confidence interval; INCS, intranasal corticosteroid; LMK-CT, Lund-Mackay computed tomography; LSM, least squares mean; Q2W, once every 2 weeks.

See the full data on sinus opacification